EAM
TMO icon

Erste Asset Management’s Thermo Fisher Scientific TMO Stock Holding History

Erste Asset Management’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.4M Sell
52,090
-14,540
-22% -$6.98M 0.21% 114
2026
Q1 		$32M Sell
66,630
-21,238
-24% -$11.5M 0.3% 89
2025
Q4 		$51.1M Buy
87,868
+27,098
+45% +$15.3M 0.43% 59
2025
Q3 		$28.1M Sell
60,770
-23,889
-28% -$11.1M 0.27% 99
2025
Q2 		$34.5M Buy
84,659
+14,306
+20% +$5.98M 0.29% 80
2025
Q1 		$35.1M Sell
70,353
-2,968
-4% -$1.61M 0.45% 58
2024
Q4 		$38.3M Sell
73,321
-26,537
-27% -$14.6M 0.47% 55
2024
Q3 		$61.5M Buy
99,858
+9,122
+10% +$5.4M 0.74% 34
2024
Q2 		$50M Sell
90,736
-2,549
-3% -$1.46M 0.66% 43
2024
Q1 		$54.1M Sell
93,285
-909
-1% -$510K 0.74% 36
2023
Q4 		$50.1M Buy
94,194
+7,203
+8% +$3.49M 0.73% 38
2023
Q3 		$43.8M Buy
86,991
+15,254
+21% +$8.13M 0.76% 32
2023
Q2 		$37M Sell
71,737
-1,682
-2% -$908K 0.65% 44
2023
Q1 		$41.5M Buy
73,419
+1,024
+1% +$577K 0.79% 32
2022
Q4 		$40.3M Sell
72,395
-1,831
-2% -$970K 0.85% 34
2022
Q3 		$38.2M Buy
74,226
+1,966
+3% +$1.1M 0.86% 27
2022
Q2 		$38.8M Sell
72,260
-11,342
-14% -$6.24M 0.86% 28
2022
Q1 		$49.7M Buy
83,602
+3,663
+5% +$2.1M 0.95% 21
2021
Q4 		$53M Sell
79,939
-235
-0.3% -$147K 0.95% 18
2021
Q3 		$46.4M Sell
80,174
-4,800
-6% -$2.63M 0.92% 22
2021
Q2 		$43.1M Buy
84,974
+19,722
+30% +$9.31M 0.86% 29
2021
Q1 		$29.5M Buy
65,252
+6,660
+11% +$3.18M 0.72% 39
2020
Q4 		$27.1M Sell
58,592
-1,728
-3% -$810K 0.75% 38
2020
Q3 		$26.3M Buy
60,320
+3,927
+7% +$1.62M 0.9% 27
2020
Q2 		$19.9M Buy
56,393
+7,880
+16% +$2.64M 0.79% 34
2020
Q1 		$13.8M Buy
48,513
+6,203
+15% +$1.96M 0.8% 30
2019
Q4 		$13.8M Buy
42,310
+1,300
+3% +$394K 0.61% 43
2019
Q3 		$11.8M Buy
41,010
+460
+1% +$132K 0.63% 42
2019
Q2 		$11.9M Sell
40,550
-2,650
-6% -$730K 0.63% 38
2019
Q1 		$11.7M Sell
43,200
-4,580
-10% -$1.14M 0.66% 32
2018
Q4 		$10.6M Buy
+47,780
New +$11.2M 0.71% 30

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Erste Asset Management's TMO Position: Q2 2026 in Review

Erste Asset Management reduced its Thermo Fisher Scientific (TMO) stake by 22% in Q2 2026, selling an estimated $6.98M and leaving 52,090 shares worth $26.4M. The position accounts for 0.21% of the portfolio, ranked #114.

Erste Asset Management first reported a position in TMO in Q4 2018 and has held it in 31 quarters since. The position peaked at $61.5M in Q3 2024. 2,604 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Erste Asset Management held 52,090 shares of Thermo Fisher Scientific worth $26.4M as of Q2 2026.
  • Erste Asset Management sold 14,540 Thermo Fisher Scientific shares in Q2 2026, an estimated $6.98M.
  • Thermo Fisher Scientific made up 0.21% of Erste Asset Management's portfolio in Q2 2026, its #114 holding.
  • Erste Asset Management first reported a position in Thermo Fisher Scientific in Q4 2018 and has held it in 31 quarters since.
  • Erste Asset Management's Thermo Fisher Scientific position peaked at $61.5M in Q3 2024.
  • 2,604 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.